Clinical Trials | A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer

The University of Virginia Comprehensive Cancer Center seeks participants 18 and over with small cell lung cancer. The purpose of this study is to test the safety of iadademstat at different doses in combination with atezolizumab or durvalumab and identify the highest dose that can be given safely in combination with either atezolizumab or durvalumab. In this study, you will get the study drug iadademstat in combination with either atezolizumab or durvalumab. You will continue treatment unless your disease gets worse, or the side effects become too severe. There is some evidence in people with small cell lung cancers and blood cancers that the study drug, iadademstat, can stabilize cancer. However, we do not know if this will happen in people with small cell lung cancer when iadademstat is combined with immune checkpoint inhibitors. It is unlikely that this drug combination will help you live longer than the usual approach alone. This study may help the study doctors learn things that may help other people in the future. If you choose to take part in this study, there is a risk that the study approach may not be as good as the usual approach for your cancer at shrinking or stabilizing your cancer. There is also a risk that you could have side effects from the study drug, iadademstat. These side effects may be worse and may be different than you would get with the usual approach for your cancer. Some of the most common side effects that the study doctors know about are: • Tiredness • Infection • Cough • Diarrhea • Loss of appetite After you finish your treatment, your doctor will continue to follow your condition for 12 months. This will include assessments every 3 months in the office. Additional information found here: https://www.clinicaltrials.gov/study/NCT06287775?term=NCT06287775&rank=1 For questions, contact: [email protected]